HIV InfectionsIMPERATIVENCT06370923
Harnessing Male Peer Networks to Enhance Engagement With HIV Prevention
A study testing Peer Distribution and Community Health Worker Distribution in people with HIV Infections, run by University of Stellenbosch at 1 site in Zimbabwe.
Trial summary
Novel strategies are needed to engage men in Sub Saharan Africa (SSA) with HIV testing, treatment and prevention services to drive the epidemic towards elimination. Suboptimal engagement with HIV prevention by men increases their risk of HIV acquisition, and is an important driver of new HIV infections in women. Read more about this study
- Who is it for?
- Ages 18 years and older, men onlyHealthy volunteers can take part
- Conditions the study is for
- HIV Infections
- What is being tested?
- Peer Distribution and Community Health Worker Distribution
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 3,591 participants
- Where
- 1 siteZimbabwe
- Study dates
- 21 Oct 2024to 31 May 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Resident in study site
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Zimbabwe1 site, 1 recruiting
- Recruiting
BRTI - Manicaland Centre for Public Health Research
Mutare, Manicaland Province
Constance Nyamukapa, PhD, nyamukapaconnie@gmail.com
About this study
Official title: Harnessing Male Peer Networks to Enhance Engagement With HIV Prevention: A Large-scale Cluster Randomized Trial to Increase HIV Self-testing and PrEP Uptake Among Men in Eastern Zimbabwe
Novel strategies are needed to engage men in Sub Saharan Africa (SSA) with HIV testing, treatment and prevention services to drive the epidemic towards elimination. Suboptimal engagement with HIV prevention by men increases their risk of HIV acquisition, and is an important driver of new HIV infections in women. HIV self-testing (HIVST) addresses several key facility-based access barriers and HIVST distribution through leveraging male peer networks for HIV prevention is feasible, acceptable and effective in SSA.
The objective of this project is to use an implementation science approach to establish the impact of HIVST distribution through male social networks, with phone-based support and improved risk perception, on PrEP (Pre-Exposure Prophylaxis) uptake among men in Eastern Zimbabwe. The project will leverage infrastructure and data associated with 20-year programme of HIV surveillance and behavioural research in a well-characterized population cohort hosted by the Manicaland Centre for Public Health Research, Zimbabwe.
The study will utilise a cluster randomised design of 44 clusters (22 Intervention:22 control) comprising on average 81 men in each cluster (total N = 3591) followed for 6 months (giving >80% power to detect a difference in PrEP initiation among men of 2% versus 8.5%). In intervention clusters the investigators will identify initial distributors who will receive an HIVST kit for personal use and HIVST kits to distribute to local peers. These peers can subsequently become distributors, allowing the intervention to propagate through peer networks. A toll-free helpline will provide pre- and post-test support and an SMS (Short Message Service) -based risk assessment will expedite PrEP initiation at the clinic. The study team will conduct a performance (process) evaluation of the intervention. to assess implementation fidelity, causal mechanisms underlying trial effectiveness including how characteristics of peer networks affect outcomes. Results of the study will be used to quantify the population level impacts and cost-effectiveness of male peer to peer HIVST distribution strategies on the uptake of PrEP in HIV hyper-endemic settings using a fully calibrated individual-based mathematical model. The envisaged long-term impact of this research is the development of a generalizable, multicomponent male peer-based HIVST and PrEP uptake model for settings where HIV incidence is high.
Read the detailed description
The study will use a cluster-randomised trial design with clusters based on existing village boundaries, which have been utilised as part of an ongoing population-based HIV surveillance. In some cases, neighbouring villages will be aggregated to give approximately equal numbers of adult men in each cluster.
The study cohort from which participants will be recruited is located in Manicaland province, east Zimbabwe.
The intervention will proceed with the following steps:
- Potential primary distributors will be identified by the research team following engagement with local key informants, these individuals will be contacted and screened for study enrolment. The desired characteristics of these individuals would be that they are members of their community with strong local networks of peers. If they choose to participate an informed consent procedure will be completed by the fieldworkers. ii. If enrolled, the distributor will be given a pack containing four HIVST kits, one for their own use and three for distribution within the cluster. The study team will collect basic demographic data (name/age / cell number) for the distributor and the intended recipients. They will also record the unique ID of the pack of kits. Advice will be provided on the correct use and interpretation of the HIVST, the need for post-test confirmatory testing in a health facility and the availability of HIV prevention methods including PrEP. iii. The distributor will be asked to give the test kits to the intended recipients within a seven-day period. iv. After seven days the helpdesk will contact the distributor and the intended recipients to ascertain whether kits have been received and used, to collect behavioural HIV risk data for the recipients and encourage attendance at a healthcare facility for a confirmatory test. If they have not yet distributed the test kits, the helpline will follow-up at regular intervals to see if distribution has happened. HIVST recipients will be invited to complete the informed consent over the telephone and be enrolled in the study. Follow-up calls will be made to these individuals if necessary. Recipients will be encouraged to consider becoming distributors and advised on the location of community facilities (shops, pharmacies, hairdressers etc.) from where they can obtain the HIVST packs for distribution. This method of HIVST distribution through community-based hubs has been proven to be successful in studies in other Sub-Saharan African settings. [48] A small incentive of USD1:00 will be transferred electronically to the initial distributor for each kit successfully distributed. Successful distribution to peers is defined as the peer having received the HIVST and has been successfully contacted by the helpline to confirm receipt of the HIVST but does not have to use the HIVST or agree to enrol in the study as a distributor. Names and cell numbers will be collected for intended recipients by the study team and stored confidentially.
- If the recipient chooses to become a distributor, they will go to the community facility and the owner will check using a real-time database that they are eligible. If they pass this screening, they will be given a pack of three HIVST kits for within cluster distribution. If distributors successfully distribute all three HIVST kits within their clusters, they will have the option to collect a further three HIVST kits (up to a total maximum of six HIVST kits) from the community facility. A small remuneration of USD1:00 will be paid to the facility owner for each pack of kits distributed. vi. After seven days the helpdesk will contact the second level recipients and steps iv) and v) will be repeated until all kits allocated to a particular community have been distributed. vii. When participants attend a clinic for confirmatory testing, they will return the referral form which was enclosed with the HIVST kit which has a unique barcode and based on their self-reported HIVST result (unreactive/reactive) be screened for PrEP or ART. The outcome of the screening will be recorded in a tick-box on the label and the packaging deposited in a secure box at the clinic from where it will be collected by the study team. viii. Referral forms, HIVST kits and HIVST packaging will be returned to the central data processing facility for data entry and an additional USD1:00 remuneration will be paid to each individual attending the clinic and participating in a confirmatory HIV test. ix. All individuals initiating PrEP or ART will be contacted monthly for six months to provide support and to ascertain whether they are still adhering to/continuing with PrEP/ART.
- Additionally, we will contact all men who report they are still taking PrEP/ART at the end of the follow-up period in order to obtain a dry blood spot to verify the self-report of adherence. This will be sent for analysis in order to assess the intracellular levels of tenofovir diphosphate (TFV-DP) in red blood cells.
- Conditions
- HIV Infections
- Being tested
- Peer Distribution, Community Health Worker Distribution
- Keywords
- HIV self test, HIV Pre Exposure Prophylaxis, Peer Networks
- Medical subject headings
- HIV Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Peer DistributionBehavioural
In intervention clusters investigators will identify initial distributors who will receive an HIVST kit for personal use and HIVST kits to distribute to local peers. These peers can subsequently become distributors, allowing the intervention to propagate through peer networks. A toll-free helpline will provide pre- and post-test support and an SMS-based risk assessment will expedite PrEP initiation at the clinic.
Community Health Worker DistributionBehavioural
Distribution of HIV self tests by community health workers
| Study group | Role | What they receive |
|---|---|---|
| Peer Distribution | Experimental | In intervention clusters investigators will identify initial distributors who will receive an HIVST kit for personal use and HIVST kits to distribute to local peers. These peers can subsequently become distributors, allowing the intervention to propagate through peer networks. A toll-free helpline will provide pre- and post-test support and an SMS-based risk assessment will expedite PrEP initiation at the clinic. Receives: Behavioral: Peer Distribution |
| Community Health Worker Distribution | Active comparator | This will be the Standard of Care, HIVST kits distributed by Community health workers in the Control clusters. Receives: Behavioral: Community Health Worker Distribution |
What is being measured
The primary outcome is the main question the study is designed to answer.
HIV pre-exposure prophylaxis (PrEP) initiation
A comparison between the intervention and control arms of the proportions of men aged 18 and above initiating PrEP
Measured: Up to 6 months from the start of HIVST distribution in the local intervention clusters
Secondary outcomes (7)
Antiretroviral Therapy initiation
A comparison between the intervention and control arms of the proportions of men aged 18 and above initiating Antiretroviral therapy
Measured: Up to 6 months from the start of HIVST distribution in the local intervention clusters
Antiretroviral Therapy or HIV pre-exposure prophylaxis (PrEP) initiation
A comparison between the intervention and control arms of the proportions of men aged 18 and above initiating Antiretroviral therapy
Measured: Up to 6 months from the start of HIVST distribution in the local intervention clusters
HIV testing
A comparison between the intervention and control arms of the proportions of men aged 18 and above taking an HIV test in the clinic.
Measured: Up to 6 months from the start of HIVST distribution in the local intervention clusters
Confirmed positive HIV test
A comparison between the intervention and control arms of the proportions of men aged 18 and above taking an HIV test in the clinic who are diagnosed HIV positive.
Measured: Up to 6 months from the start of HIVST distribution in the local intervention clusters
HIV testing after the use of an HIV self test
A comparison between the intervention and control arms of the proportions of men aged 18 and above taking an HIV test in the clinic after using an HIV test in the previous three months.
Measured: Up to 6 months from the start of HIVST distribution in the local intervention clusters
Attendance at first PrEP follow-up visit
A comparison between the intervention and control arms of the proportions of men aged 18 and above initiating PrEP who return for their first follow-up visit.
Measured: Up to 8 months from the start of HIVST distribution in the local intervention clusters
Attendance at first ART follow-up visit
A comparison between the intervention and control arms of the proportions of men aged 18 and above initiating ART who return for their first follow-up visit.
Measured: Up to 8 months from the start of HIVST distribution in the local intervention clusters
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Apr 2024
- Study start21 Oct 2024
- Primary completion31 May 2028 (estimated)
- Study completion31 May 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for HIV InfectionsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Cluster randomised trial
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 3,591 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Stellenbosch
- Sponsor type
- University, hospital or other
- Collaborators
- Biomedical Research and Training Institute, Zimbabwe, Imperial College London, University of Lincoln, University College London Hospitals, University of Copenhagen, University of Washington, Heidelberg University
- Responsible party
- Principal investigator, Frank Tanser, University of Stellenbosch
- Investigators
- Frank Tanser, PhD, Principal investigator, University of Stellenbosch
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06370923
- Sponsor's protocol ID
- 1R01MH133488-01
- Acronym
- IMPERATIVE
- Status last verified
- May 2025
- First submitted
- 18 Mar 2024
- Last updated
- 4 May 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Mee P, Otambo W, Skovdal M, Harling G, Pickles M, Dobra A, Hallett T, Barnighausen T, McGowan M, Inghels M, Mandizvidza P, Moorhouse L, Tsenesa B, Maswera R, Dzamatira F, Gregson S, Nyamukapa C, Tanser F. IMPERATIVE: Harnessing male peer networks to enhance engagement with HIV prevention: A large-scale cluster randomised trial to increase HIV self-testing and PrEP uptake among men in Eastern Zimbabwe. Res Sq [Preprint]. 2026 Jun 5:rs.3.rs-9814858. doi: 10.21203/rs.3.rs-9814858/v1.
PubMed 42281985
Study at a glance
From the registry record, last updated by the sponsor on 4 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Harnessing Male Peer Networks to Enhance Engagement With HIV Prevention: A Large-scale Cluster Randomized Trial to Increase HIV Self-testing and PrEP Uptake Among Men in Eastern Zimbabwe
- ClinicalTrials.gov ID
- NCT06370923
- Acronym / sponsor ID
- IMPERATIVE / 1R01MH133488-01
- Conditions
- HIV Infections
- Keywords
- HIV self test, HIV Pre Exposure Prophylaxis, Peer Networks
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 3,591 participants (estimated)
- Lead sponsor
- University of StellenboschUniversity, hospital or other
- Collaborators
- Biomedical Research and Training Institute, Zimbabwe, Imperial College London, University of Lincoln, University College London Hospitals, University of Copenhagen, University of Washington, Heidelberg University
- Study start
- 21 Oct 2024 (actual)
- Primary completion
- 31 May 2028 (estimated)
- Study completion
- 31 May 2028 (estimated)
- First posted
- 17 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Novel strategies are needed to engage men in Sub Saharan Africa (SSA) with HIV testing, treatment and prevention services to drive the epidemic towards elimination. Suboptimal engagement with HIV prevention by men increases their risk of HIV acquisition, and is an important driver of new HIV infections in women. HIV self-testing (HIVST) addresses several key facility-based access barriers and HIVST distribution through leveraging male peer networks for HIV prevention is feasible, acceptable and effective in SSA.
The objective of this project is to use an implementation science approach to establish the impact of HIVST distribution through male social networks, with phone-based support and improved risk perception, on PrEP (Pre-Exposure Prophylaxis) uptake among men in Eastern Zimbabwe. The project will leverage infrastructure and data associated with 20-year programme of HIV surveillance and behavioural research in a well-characterized population cohort hosted by the Manicaland Centre for Public Health Research, Zimbabwe.
The study will utilise a cluster randomised design of 44 clusters (22 Intervention:22 control) comprising on average 81 men in each cluster (total N = 3591) followed for 6 months (giving >80% power to detect a difference in PrEP initiation among men of 2% versus 8.5%). In intervention clusters the investigators will identify initial distributors who will receive an HIVST kit for personal use and HIVST kits to distribute to local peers. These peers can subsequently become distributors, allowing the intervention to propagate through peer networks. A toll-free helpline will provide pre- and post-test support and an SMS (Short Message Service) -based risk assessment will expedite PrEP initiation at the clinic. The study team will conduct a performance (process) evaluation of the intervention. to assess implementation fidelity, causal mechanisms underlying trial effectiveness including how characteristics of peer networks affect outcomes. Results of the study will be used to quantify the population level impacts and cost-effectiveness of male peer to peer HIVST distribution strategies on the uptake of PrEP in HIV hyper-endemic settings using a fully calibrated individual-based mathematical model. The envisaged long-term impact of this research is the development of a generalizable, multicomponent male peer-based HIVST and PrEP uptake model for settings where HIV incidence is high.
Detailed description
The study will use a cluster-randomised trial design with clusters based on existing village boundaries, which have been utilised as part of an ongoing population-based HIV surveillance. In some cases, neighbouring villages will be aggregated to give approximately equal numbers of adult men in each cluster.
The study cohort from which participants will be recruited is located in Manicaland province, east Zimbabwe.
The intervention will proceed with the following steps:
- Potential primary distributors will be identified by the research team following engagement with local key informants, these individuals will be contacted and screened for study enrolment. The desired characteristics of these individuals would be that they are members of their community with strong local networks of peers. If they choose to participate an informed consent procedure will be completed by the fieldworkers. ii. If enrolled, the distributor will be given a pack containing four HIVST kits, one for their own use and three for distribution within the cluster. The study team will collect basic demographic data (name/age / cell number) for the distributor and the intended recipients. They will also record the unique ID of the pack of kits. Advice will be provided on the correct use and interpretation of the HIVST, the need for post-test confirmatory testing in a health facility and the availability of HIV prevention methods including PrEP. iii. The distributor will be asked to give the test kits to the intended recipients within a seven-day period. iv. After seven days the helpdesk will contact the distributor and the intended recipients to ascertain whether kits have been received and used, to collect behavioural HIV risk data for the recipients and encourage attendance at a healthcare facility for a confirmatory test. If they have not yet distributed the test kits, the helpline will follow-up at regular intervals to see if distribution has happened. HIVST recipients will be invited to complete the informed consent over the telephone and be enrolled in the study. Follow-up calls will be made to these individuals if necessary. Recipients will be encouraged to consider becoming distributors and advised on the location of community facilities (shops, pharmacies, hairdressers etc.) from where they can obtain the HIVST packs for distribution. This method of HIVST distribution through community-based hubs has been proven to be successful in studies in other Sub-Saharan African settings. [48] A small incentive of USD1:00 will be transferred electronically to the initial distributor for each kit successfully distributed. Successful distribution to peers is defined as the peer having received the HIVST and has been successfully contacted by the helpline to confirm receipt of the HIVST but does not have to use the HIVST or agree to enrol in the study as a distributor. Names and cell numbers will be collected for intended recipients by the study team and stored confidentially.
- If the recipient chooses to become a distributor, they will go to the community facility and the owner will check using a real-time database that they are eligible. If they pass this screening, they will be given a pack of three HIVST kits for within cluster distribution. If distributors successfully distribute all three HIVST kits within their clusters, they will have the option to collect a further three HIVST kits (up to a total maximum of six HIVST kits) from the community facility. A small remuneration of USD1:00 will be paid to the facility owner for each pack of kits distributed. vi. After seven days the helpdesk will contact the second level recipients and steps iv) and v) will be repeated until all kits allocated to a particular community have been distributed. vii. When participants attend a clinic for confirmatory testing, they will return the referral form which was enclosed with the HIVST kit which has a unique barcode and based on their self-reported HIVST result (unreactive/reactive) be screened for PrEP or ART. The outcome of the screening will be recorded in a tick-box on the label and the packaging deposited in a secure box at the clinic from where it will be collected by the study team. viii. Referral forms, HIVST kits and HIVST packaging will be returned to the central data processing facility for data entry and an additional USD1:00 remuneration will be paid to each individual attending the clinic and participating in a confirmatory HIV test. ix. All individuals initiating PrEP or ART will be contacted monthly for six months to provide support and to ascertain whether they are still adhering to/continuing with PrEP/ART.
- Additionally, we will contact all men who report they are still taking PrEP/ART at the end of the follow-up period in order to obtain a dry blood spot to verify the self-report of adherence. This will be sent for analysis in order to assess the intracellular levels of tenofovir diphosphate (TFV-DP) in red blood cells.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Cluster randomised trial
| Arm | Type | Receives |
|---|---|---|
| Peer Distribution | Experimental | Behavioral: Peer DistributionIn intervention clusters investigators will identify initial distributors who will receive an HIVST kit for personal use and HIVST kits to distribute to local peers. These peers can subsequently become distributors, allowing the intervention to propagate through peer networks. A toll-free helpline will provide pre- and post-test support and an SMS-based risk assessment will expedite PrEP initiation at the clinic. |
| Community Health Worker Distribution | Active comparator | Behavioral: Community Health Worker DistributionThis will be the Standard of Care, HIVST kits distributed by Community health workers in the Control clusters. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Resident in study site
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Peer DistributionIn intervention clusters investigators will identify initial distributors who will receive an HIVST kit for personal use and HIVST kits to distribute to local peers. These peers can subsequently become distributors, allowing the intervention to propagate through peer networks. A toll-free helpline will provide pre- and post-test support and an SMS-based risk assessment will expedite PrEP initiation at the clinic. | Behavioural | Peer Distribution |
| Community Health Worker DistributionDistribution of HIV self tests by community health workers | Behavioural | Community Health Worker Distribution |
Primary outcome
HIV pre-exposure prophylaxis (PrEP) initiation
Time frame: Up to 6 months from the start of HIVST distribution in the local intervention clusters
A comparison between the intervention and control arms of the proportions of men aged 18 and above initiating PrEP
7 secondary outcomes
Antiretroviral Therapy initiation
Time frame: Up to 6 months from the start of HIVST distribution in the local intervention clusters
Antiretroviral Therapy or HIV pre-exposure prophylaxis (PrEP) initiation
Time frame: Up to 6 months from the start of HIVST distribution in the local intervention clusters
HIV testing
Time frame: Up to 6 months from the start of HIVST distribution in the local intervention clusters
Confirmed positive HIV test
Time frame: Up to 6 months from the start of HIVST distribution in the local intervention clusters
HIV testing after the use of an HIV self test
Time frame: Up to 6 months from the start of HIVST distribution in the local intervention clusters
Attendance at first PrEP follow-up visit
Time frame: Up to 8 months from the start of HIVST distribution in the local intervention clusters
Attendance at first ART follow-up visit
Time frame: Up to 8 months from the start of HIVST distribution in the local intervention clusters
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 May 2025.
- Derived from this study: PubMed 42281985Mee P, Otambo W, Skovdal M, Harling G, Pickles M, Dobra A, Hallett T, Barnighausen T, McGowan M, Inghels M, Mandizvidza P, Moorhouse L, Tsenesa B, Maswera R, Dzamatira F, Gregson S, Nyamukapa C, Tanser F. IMPERATIVE: Harnessing male peer networks to enhance engagement with HIV prevention: A large-scale cluster randomised trial to increase HIV self-testing and PrEP uptake among men in Eastern Zimbabwe. Res Sq [Preprint]. 2026 Jun 5:rs.3.rs-9814858. doi: 10.21203/rs.3.rs-9814858/v1.
Related trials for HIV Infections
Not yet recruiting
HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea
HIV Infections, HIV Prevention and Care
Not yet recruiting
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Recruiting
Evaluating the Impact of Using the B-OK Bottles for HIV and ART Literacy in South Africa
HIV, HIV Treatment
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Frank Tanser, PhD principal investigator
University of Stellenbosch
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Peer Distribution and Community Health Worker Distribution in people with HIV Infections, run by University of Stellenbosch at 1 site in Zimbabwe.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Zimbabwe. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Constance Nyamukapa, PhD (+263 71 480 4050, nyamukapaconnie@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
HIV pre-exposure prophylaxis (PrEP) initiation (time frame: Up to 6 months from the start of HIVST distribution in the local intervention clusters). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06370923, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2025.